{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:55:17Z","timestamp":1791363317478,"version":"4.3.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01852-0","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:43:31Z","timestamp":1791362611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Oriol","family":"Mirallas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"16suppl","key":"1852_CR1","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2026.44.16_suppl.8012","volume":"44","author":"Z Hao","year":"2026","unstructured":"Hao Z, Chiappori A, Creelan BC, Munker R, Schwarzenberger PO, Patel N, et al. Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC. J Clin Oncol. 2026;44(16suppl):8012. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.8012.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR2","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.2026.44.16_suppl.2557","volume":"44","author":"C Liu","year":"2026","unstructured":"Liu C, Qi C, Gong J, Liu D, Zhang P, Qin Y, et al. Long-term follow-up of satricabtagene autoleucel (satri-cel) as sequential therapy after first-line treatment for advanced gastric cancer: a subgroup analysis. J Clin Oncol. 2026;44(16suppl):2557. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2557.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR3","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2026.44.16_suppl.2508","volume":"44","author":"J Fan","year":"2026","unstructured":"Fan J, Zhou J, Huang XW, Gao Q, Shi J, Cheng XB, et al. Objective response rates with Ori-C101, an armored GPC3-directed CAR-T, in heavily pretreated advanced HCC: updated results from the phase Ib BEACON study. J Clin Oncol. 2026;44(16suppl):2508. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2508.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR4","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1200\/JCO.2026.44.16_suppl.8579","volume":"44","author":"JR Molina","year":"2026","unstructured":"Molina JR, Ward J, Hecht JR, Kirtane K, Marar R, Fankuchen OR, et al. Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)-targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH). J Clin Oncol. 2026;44(16suppl):8579. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.8579.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR5","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1200\/JCO.2026.44.16_suppl.3514","volume":"44","author":"H Zhang","year":"2026","unstructured":"Zhang H, Li J, Gao Y, Zhang Y, Zhu X, Wang L, et al. Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases. J Clin Oncol. 2026;44(16suppl):3514. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.3514.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR6","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2026.44.16_suppl.2542","volume":"44","author":"X Ding","year":"2026","unstructured":"Ding X, Zhang W, Teng Y, Du CX, Qiao W, Jin R, et al. Phase 1 trial of a KRAS G12V\/HLA-A*11:01-restricted TCR-engineered T-cell therapy in advanced solid tumors. J Clin Oncol. 2026;44(16suppl):2542. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2542.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR7","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2026.44.16_suppl.9508","volume":"44","author":"D Davar","year":"2026","unstructured":"Davar D, Patel SP, Hernandez-Aya LF, Holderried TAW, Busse A, Tsimberidou AM, et al. Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy. J Clin Oncol. 2026;44(16suppl):9508. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.9508.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR8","doi-asserted-by":"publisher","first-page":"11516","DOI":"10.1200\/JCO.2026.44.16_suppl.11516","volume":"44","author":"DM Araujo","year":"2026","unstructured":"Araujo DM, Chatterjee M, Davar D, Hernandez-Aya LF, Reshef R, Pankov D, et al. Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma. J Clin Oncol. 2026;44(16suppl):11516. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.11516.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR9","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1200\/JCO.2026.44.16_suppl.5509","volume":"44","author":"A Busse","year":"2026","unstructured":"Busse A, Alsdorf W, Yeku OO, Taylor SE, Araujo DM, Jaeger D, et al. Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer. J Clin Oncol. 2026;44(16suppl):5509. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.5509.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR10","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1200\/JCO.2026.44.16_suppl.11505","volume":"44","author":"SP D\u2019Angelo","year":"2026","unstructured":"D\u2019Angelo SP, Araujo DM, Razak A, Agulnik M, Butler MO, Druta M, et al. Pooled analyses of clinical outcomes with afamitresgene autoleucel (afami-cel) in metastatic synovial sarcoma. J Clin Oncol. 2026;44(16suppl):11505. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.11505.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1852_CR11","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/JCO.2026.44.16_suppl.2506","volume":"44","author":"R Surana","year":"2026","unstructured":"Surana R, Schoenfeld AJ, Kamgar M, Dumbrava EE, Paulson AS, Becerra CR, et al. Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H-mutated unresectable advanced solid tumors. J Clin Oncol. 2026;44(16suppl):2506. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2506.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01852-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01852-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01852-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:43:31Z","timestamp":1791362611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01852-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01852-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a review of publicly available data and did not involve human participants; therefore, institutional ethics approval and informed consent were not required. The manuscript was prepared in accordance with the Committee on Publication Ethics (COPE) guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"82"}}